We utilized a PD-L1 positivity definition as > 0% positive cells (i.e. when any tumor cell positivity was detected) given that the correlation between specific PD-L1 levels and inhibition of anti-cancer immunity is not currently well-established and that the optimal cutoff for PD-L1 expression as a biomarker for response to treatment is still unknown. This evidence concerns the gene CD274 and cancer.